Cullinan Therapeutics, Inc. (CGEM) Dividend History

Company News

• Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

  Cullinan Therapeutics received approval from the European Medicines Agency to initiate a Phase 1 trial of its bispecific CD19 T cell engager CLN-978 in patients with rheumatoid arthritis. The trial will be conducted at research institutions in Germany and Italy, and CLN-978 is also being studied for systemic lupus erythematosus.

  GlobeNewswire Inc.
• Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

  Cullinan Therapeutics reported progress in its pipeline, including initial clinical data for CLN-978 in Systemic Lupus Erythematosus expected in Q4 2025 and positive results from the pivotal Phase 2b study of zipalertinib. The company ended 2024 with $606.9 million in cash, providing runway into 2028.

  GlobeNewswire Inc.
• Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

  Cullinan Therapeutics will present new preclinical data for its CD19-directed T cell engager CLN-978 at the ACR Convergence 2024 conference. The data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in cells from patients with SLE or RA as compared to healthy volunteers, suggesting a broad therapeutic potential. Cullinan plans to initiate a global Phase 1b study of CLN-978 in patients with moderate to severe SLE.

  GlobeNewswire Inc.
• Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

  Amgen's rocatinlimab outperformed placebo in an atopic dermatitis trial, but the data fell short of market leader Dupixent's results, raising concerns about its competitiveness. Uplizna, Amgen's treatment for myasthenia gravis, showed promising results in a Phase 3 trial, with potential advantages like less frequent dosing.

  Benzinga

  Featured Companies: AMGN REGN
• Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

  Cullinan Therapeutics presented positive updated data from its pivotal Phase 2b study of zipalertinib in patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on prior amivantamab treatment. The data showed a consistent objective response rate of 40% and a manageable safety profile.

  GlobeNewswire Inc.